Merck & Co.

Current directors and officers who also hold a role at another S&P 500 company.

• Patricia F. RussoGM · DirectorHPE · DirectorKKR · Director
• Pamela J. CraigGLW · DirectorPGR · Director
• Caroline LitchfieldVZ · Director
• Douglas M. Baker, Jr.TGT · Director
• Joseph RomanelliKMB · Director
• Kathy J. WardenNOC · CEO
• Paul RothmanLH · Director
• Robert M. DavisDUK · Director
• Surendralal Lanca KarsanbhaiEMR · CEO
• Thomas H. GlocerMS · Director

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

No 5% holder filings parsed yet for this company.

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. Oct 13, 2026

   (d) Incorporated by reference is a press release issued by Merck & Co., Inc. (the “Company”) on October 13, 2026, attached as Exhibit 99.1, announcing the election of Paul J. Diaz to the Company’s Board of Directors (the “Board”), effective November 1, 2026. The Board appointed Mr. Diaz as a member of both the Audit Committee and the Research Committee of the Board. For his service on the Board, Mr. Diaz will receive compensation as a non-employee director in accordance with the Company’s non-employee director compensation practices described under the “Director Compensation” section of the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 8, 2026. Mr.

   Read the 8-K filing
2. Nov 22, 2024

   (d) Incorporated by reference is a press release issued by Merck & Co., Inc. (the “Company”) on November 22, 2024, attached as Exhibit 99.1, announcing the election of Surendralal L. “Lal” Karsanbhai to the Company’s Board of Directors (the “Board”), effective January 1, 2025. The Board appointed Mr. Karsanbhai as a member of both the Audit and Governance Committees of the Board. For his service on the Board, Mr. Karsanbhai will receive compensation as a non-employee director in accordance with the Company’s non-employee director compensation practices described under the “Director Compensation” section of the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 11, 2024. Mr.

   Read the 8-K filing
3. Feb 20, 2024

   Election of Directors; Appointment of Certain Officers; Compensatory Arrangment of Certain Officers. (b) On February 15, 2024, Peter C. Wendell gave notice to Merck & Co., Inc. (the “Company”) of his intention to retire from the Board of Directors of the Company (the “Board”) as of the Company’s 2024 Annual Meeting of Shareholders on May 28, 2024. Mr. Wendell’s retirement from the Board is not due to any disagreement with the Company with respect to any matter relating to the Company’s operations, policies or practices.

   Read the 8-K filing
4. Nov 28, 2023

   (b) Resignation of Certain Officers On November 21, 2023, Rita Karachun, Senior Vice President Finance – Global Controller and principal accounting officer of Merck & Co., Inc. (the “Company”), gave notice of her intention to resign from this position effective December 4, 2023. Ms. Karachun plans to retire from the Company in 2024. Ms. Karachun’s resignation is not due to any disagreement with the Company with respect to any matter relating to the Company’s operations, policies or practices. (c) Appointment of Certain Officers On November 28, 2023, the Board of Directors (the “Board”) of the Company elected Dalton E. Smart III to serve as Senior Vice President Finance – Global Controller of the Company, effective December 4, 2023, making him the Company’s principal accounting officer. Mr. Smart, 57 years old, has served as Assistant Controller of the Company since September 2023.

   Read the 8-K filing
5. Oct 27, 2022

   Election of Directors; Appointment of Certain Officers; Compensatory Arrangment of Certiain Officers. (b) Merck announced that Kenneth C. Frazier, the Executive Chairman of Merck’s Board of Directors (the “Board”) will retire from the Board, effective November 30, 2022. In addition, on October 26, 2022, the Board unanimously elected Robert M. Davis, Merck’s current Chief Executive Officer and President as well as a Director on the Board to serve as Chairman of the Board, effective December 1, 2022. On October 26, 2022, the Company issued a press release announcing the foregoing. The press release is attached as Exhibit 99.3 and incorporated herein by reference.

   Read the 8-K filing
6. Aug 20, 2021

   (b) Incorporated by reference is a press release issued by Merck & Co., Inc. (the “Company”) on August 20, 2021, attached as Exhibit 99.1, announcing the resignation of Leslie A. Brun from the Company’s Board of Directors effective August 19, 2021.

   Read the 8-K filing
7. Mar 26, 2021

   (c) On February 4, 2021, Merck & Co., Inc. (the “Company”) announced that Kenneth C. Frazier, the Company’s Chairman and Chief Executive Officer, will retire as Chief Executive Officer, effective June 30, 2021. After his retirement, Mr. Frazier will continue as Executive Chairman of the Company for a transition period to be determined by the Company’s Board of Directors (the “Board”). In addition, the Board unanimously elected Robert M. Davis, the Company’s current Executive Vice President, Global Services and Chief Financial Officer, to serve as President of the Company, effective April 1, 2021, and as the Company’s Chief Executive Officer and a member of the Board, effective July 1, 2021. In connection with the CEO transition between Mr. Frazier and Mr.

   Read the 8-K filing
8. Feb 4, 2021

   (b)(c)(d) Merck & Co., Inc. (the “Company”) announced that Kenneth C. Frazier, the Company’s Chairman and Chief Executive Officer will retire as Chief Executive Officer, effective June 30, 2021. After his retirement, Mr. Frazier will continue as Executive Chairman of the Company for a transition period to be determined by the Board of Directors (“Board”). In addition, on February 1, 2021, the Board unanimously elected Robert M. Davis, age 54, the Company’s current Executive Vice President, Global Services and Chief Financial Officer, to serve as President of the Company, effective April 1, 2021, and as the Chief Executive Officer and a director of the Company, effective July 1, 2021. On February 4, 2021, the Company issued a press release (the “Press Release”) announcing the foregoing. The Press Release is attached as Exhibit 99.1 and incorporated herein by reference.

   Read the 8-K filing
9. Feb 1, 2021

   (d) Incorporated by reference is a press release issued by Merck & Co., Inc. (the “Company”) on February 1, 2021, attached as Exhibit 99.1, announcing the election of Stephen L. Mayo to the Company’s Board of Directors (the “Board”), effective March 15, 2021. The Board appointed Dr. Mayo as a member of both the Research Committee and the Audit Committee of the Board. For his service on the Board, Dr. Mayo will receive compensation as a non-employee director in accordance with the Company’s non-employee director compensation practices described under the “Director Compensation” section of the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 6, 2020. Dr.

   Read the 8-K filing
10. Jan 31, 2020

    (d) Incorporated by reference is a press release issued by Merck & Co., Inc. (“Merck” or the “Company”) on January 31 , 2020, attached as Exhibit 99.1, announcing the election of Kathy J. Warden and Christine E. Seidman, M.D. to the Company’s Board of Directors (the “Board”), effective March 16, 2020. The Board appointed each of Ms. Warden and Dr. Seidman as a member of both the Audit Committee and the Research Committee of the Board. For their service on the Board, Ms. Warden and Dr. Seidman will receive compensation as non-employee directors in accordance with the Company’s non-employee director compensation practices described under the “Director Compensation” section of the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 8, 2019. Neither Ms. Warden nor Dr.

    Read the 8-K filing
11. Jan 30, 2019

    Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 30, 2019 (January 29, 2019) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey 1-6571 22-1918501 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 2000 Galloping Hill Road, Kenilworth, NJ 7033 (Address of principal executive offices) (Zip code) Registrant’s telephone number, including area code: (908) 740-4000 Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ¨ Written commu…

    Read the 8-K filing
12. Dec 10, 2018

    RESIGNATION AS Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 10, 2018 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey 1-6571 22-1918501 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 2000 Galloping Hill Road, Kenilworth, NJ 07033 (Address of principal executive offices) (Zip code) Registrant’s telephone number, including area code: (908) 740-4000 Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ¨ Written communi…

    Read the 8-K filing
13. Oct 4, 2018

    (b) On October 2, 2018, Craig B. Thompson, M.D., notified Merck & Co., Inc. (“Merck” or the “Company”) of his resignation from the Board of Directors, effective immediately. Dr. Thompson’s resignation from the Company’s Board of Directors was not related to any disagreement with the Company on any matter related to the Company’s operations, policies or practices. As a result of Dr. Thompson’s resignation, the size of the Company’s Board of Directors has been reduced from 13 to 12 directors, effective October 3, 2018. 2

    Read the 8-K filing
14. Sep 27, 2018

    (e) Merck announced on September 26, 2018, that its Board of Directors has rescinded its policy subjecting the Company’s Chief Executive Officer to mandatory retirement at age 65. Merck also announced that its current Chief Executive Officer, Kenneth C. Frazier, has agreed to remain in his position beyond December 2019, when he turns 65. Because the revision of this policy causes Mr. Frazier to lose pension benefits of approximately $2.5 million to which he would have been entitled upon his mandatory retirement, the Board also granted Mr. Frazier, subject to certain conditions, $2.5 million in deferred compensation.

    Read the 8-K filing
15. Feb 26, 2018

    (b) On February 21, 2018, Michael J. Holston, Executive Vice President and General Counsel of Merck & Co., Inc. (“Merck” or the “Company”), notified the Company that he will resign from his position with the Company effective April 1, 2018. Mr. Holston will accept an offer from General Electric Company to serve as the Senior Vice President, General Counsel and Secretary. 2

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.